Methods for treating osteogenesis imperfecta
AssigneesGenzyme Corporation, Baylor College of Medicine
InventorsBrendan Lee, Kuber T. Sampath
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).
Claims20
A method for treating osteogenesis imperfecta (OI) in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding fragment thereof that binds to transforming growth factor β (TGFβ), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising the amino acid sequences of
- SEQ ID NOs:
- 22 and 23, respectively, or
- SEQ ID NOs:
- 24 and 25, respectively.
A method of treating osteogenesis imperfecta (OI) in a human subject in need thereof, comprising:
- selecting a human subject who has OI and has been determined to have a mutated gene for Type I or Type II collagen, leucine proline-enriched proteoglycan (leprecan), or cartilage associated protein (CRTAP);
- and
- administering to the subject a therapeutically effective amount of an antibody or an antigen-binding fragment thereof that binds to transforming growth factor β (TGFβ), wherein the antibody or antigen-binding fragment comprises heavy chain complementarity-determining regions (CDRs) 1-3 having the amino acid sequences of SEQ ID NOs:
- 4, 5, and 6, respectively;
- and light chain CDR1-3 having the amino acid sequences of SEQ ID NOs:
- 7, 8, and 9, respectively.
A method of treating osteogenesis imperfecta (OI) in a human subject in need thereof, comprising:
- administering to the subject an antibody or an antigen-binding fragment thereof that binds to transforming growth factor β (TGFβ), wherein the antibody or antigen-binding fragment comprises heavy chain complementarity-determining regions (CDRs) 1-3 having complementarity determining regions (CDRs) 1-3 having the amino acid sequences of SEQ ID NOs:
- 4, 5, and 6, respectively;
- and light chain CDR1-3 having the amino acid sequences of SEQ ID NOs:
- 7, 8, and 9, respectively;
- and
- measuring the level of (1) one or more biomarkers of bone deposition selected from type 1 procollagen (C-terminal/N-terminal), osteocalcin, total alkaline phosphatase, and bone-specific alkaline phosphatase, or (2) one or more biomarkers of bone resorption selected from urinary hydroxyproline, urinary total pyridinoline, urinary free deoxypyridinoline, urinary collagen type-I cross-linked N-telopeptide, urinary or serum collagen type-I cross-linked C-telopeptide, bone sialoprotein, osteopontin, and tartrate-resistant acid phosphatase 5b.
Dependencies are inferred from the claim text.